Monitoring the safe use of clozapine : A consensus view from Victoria, Australia

Clozapine is an important antipsychotic agent that has a unique profile of clinical benefits, but that has also been associated with several serious and potentially life-threatening safety concerns. In order to minimise the impact of haematological adverse events, health professionals treating patie...

Full description

Saved in:
Bibliographic Details
Published in:CNS drugs 2007-01, Vol.21 (2), p.117-127
Main Authors: BERK, Michael, FITZSIMONS, Joanna, KULURIS, Bill, CALLALY, Tom, DODD, Seetal, LAMBERT, Timothy, PANTELIS, Christos, KULKARNI, Jayashri, CASTLE, David, RYAN, Elizabeth W, JESPERSEN, Sean, MCGORRY, Pat, BERGER, Gregor
Format: Article
Language:English
Subjects:
Agranulocytosis - chemically induced
Antipsychotic Agents - adverse effects
Antipsychotic Agents - blood
Antipsychotic Agents - therapeutic use
Australia - epidemiology
Biological and medical sciences
Clozapine - adverse effects
Clozapine - blood
Clozapine - therapeutic use
Consensus
Diabetes Mellitus - chemically induced
Drug toxicity and drugs side effects treatment
Humans
Hyperlipidemias - chemically induced
Medical sciences
Neuropharmacology
Neutropenia - chemically induced
Pharmacology. Drug treatments
Population Surveillance
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Psychotic Disorders - drug therapy
Toxicity: blood
Weight Gain - drug effects
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clozapine is an important antipsychotic agent that has a unique profile of clinical benefits, but that has also been associated with several serious and potentially life-threatening safety concerns. In order to minimise the impact of haematological adverse events, health professionals treating patients with clozapine are currently required to register their patients on a centrally administered data network and to conform to strict protocols. The consensus statement documented in this article extends existing protocols by recommending monitoring of patients treated with clozapine for additional adverse effects during treatment. This consensus statement reflects the current practice at five major public psychiatric hospitals in Victoria, Australia, for the monitoring and management of clozapine-related adverse events, and has been implemented at these sites because of emerging safety concerns associating clozapine with cardiovascular and metabolic adverse effects.
ISSN:1172-7047
1179-1934
DOI:10.2165/00023210-200721020-00003